Remove 2005 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Pharma within planetary boundaries

European Pharmaceutical Review

4 Together with a legal expert from the Bucerius Law School Hamburg, we looked at the legal and political frameworks that could enable the German pharmaceutical sector to become more sustainable. European Pharmaceutical Strategy – European Commission (draft) Pharmaceutical package. Available from: [link].

article thumbnail

Why Are FDA Inspections So Ineffective and Disappointing?

The People's Pharmacy

The same was true of another of the company’s products, Delsam Pharma Artificial Eye Ointment , which the company voluntarily recalled shortly after. “The FDA said Global Pharma failed to use adequate, tamper-evident packaging and distributed the drugs without proper preservatives.”

FDA 72
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A New Regulatory Approach to Drive Sustainable Medicines

ISPE

As such there’s a growing question of how the industry will improve the sustainability profile of its existing medicines and ensure that sustainability is designed into new medicines, such as products, with a reduced environmental risk, greener manufacturing technologies, and recyclable delivery systems and packaging. 9 December 2021.

article thumbnail

Twenty Women Leaders In Healthcare Industry

PharmaShots

Other Affiliations: Angela is an active Board of Director member of the Pfizer Foundation (a charitable organization addressing global health challenges), European Federation of Pharmaceutical Industries and Associations (EFPIA), and UPS (the global leader in package delivery and supply chain logistics).

FDA 40
article thumbnail

CMC Requirements for New Drug Registration in Latin America

ISPE

In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements.